Received Apr 2, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMXB072A | — |
Menveo(2-vial)- Inadvertent Administration of Only the MenCYW-135 Liquid Conjugate Component of the 2-vial Presentation of Menveo; Menveo(2-vial)- Inadvertent Administration of Only the MenCYW-135 Liquid Conjugate Component of the 2-vial Presentation of Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 16-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMXB072A, expiry date 31-DEC-2026) for prophylaxis. On 26-MAR-2026, the patient received Menveo. On 26-MAR-2026, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: Menveo(2-vial)- Inadvertent Administration of Only the MenCYW-135 Liquid Conjugate Component of the 2-vial Presentation of Menveo) and inappropriate dose of vaccine administered (Verbatim: Menveo(2-vial)- Inadvertent Administration of Only the MenCYW-135 Liquid Conjugate Component of the 2-vial Presentation of Menveo). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 26-MAR-2026 The reporter reported that a patient was administered only the liquid component of the Menveo (2 vial) vaccine on 26 March 2026.